

х.	MANE	TRANSMITTAL LETTER				Case No. 10466/64					
11	Derial No 09/904,	•				Examiner To be assigned			Group Art Unit 1645		
	Inventor	Inventor(s) Ashkenazi et al.									
	Title of I	Title of Invention SECRETED AND TRANSMEMBRANE POLYPEPTIDES AND NUCLEIC ACIDS ENCODING THE SAME									
	TO THE COMMISSIONER FOR PATENTS										
		Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); copy of Sequence Listing in computeredable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and Amino Acid Sequence Disclosures and return postcard.  Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previous submitted.								computer	
										reviously	
		A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.  Petition for amonth extension of time.									
	$\boxtimes$	No additional fee is required.									
		The fee has been calculated as shown below:									
		Other That									
ı						$\neg$	Small	Entity	$\neg$	Small	Entity
		Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra		Rate	Add'I Fee	or	Rate	Add'I Fee
	Total		Minus				x \$9=			x \$18=	
	Indep.		Minus				x 42=		_	x \$84=	
	First Pres	sentation of Mult	tiple Dep. Cl	aim			+ \$140 =		4	+ \$280=	
							Total add'I fee	\$		Total add'I fee	\$
		Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amo							nount of \$	A	
		A check in the amount of \$ to cover the filing fee is enclosed.								•	
		The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.									
I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-15 duplicate copy of this sheet is enclosed.											
	Gregory M. Zinkl, Ph.D. Registration No. 48,492										
	Agent for Applicant BRINKS HOFER GILSON & LIONE P.O. BOX 10395										

CHICAGO, ILLINOIS 60610 (312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as express mail, label no. EL 392680662US, with sufficient postage, in an envelope suffressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on 61725

Signature:

rev. Dec.-00

SHENTE TRAC

rev. Dec.-00

Serial No.	TRANSMITTAL LET	TER	Case No. 10466/64
Serial No.	Filing Date	Examiner	Group Art Unit
09/904,877	July 12, 2001	To be assigned	1645
Inventor(s)			
Ashkenazi et al.			
Title of Invention			
SECRETED AND TRANSM	IEMBRANE POLYPEPTIDES AN	ND NUCLEIC ACIDS ENCODING	THE SAME

TO THE COMMISSIONER FOR PATENTS									
Transmitted herewith is a Statement According to 37C.F.R. § 1.821(f); copy of Sequence Listing in computer readable form; copy of Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and return postcard.									
	Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.								
	A verified statement to establish small entity status under 37 CFR §§ 1.9 and 1.27 is enclosed.								
	Petition for amonth extension of time.								
$\boxtimes$	No additional fee is required.								
	The fee has been calculated as shown below:								
	Other Than Small Entity Small Entity								
	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Add'I Fee	or	Rate	Add'l Fee
Total		Minus			x \$9=			x \$18=	
Indep.		Minus			x 42=			x \$84=	
First Pre	sentation of Mul	tiple Dep. C	aim	<u></u>	+ \$140 =	<u> </u>		+ \$280=	
				·	Total add'l fee	\$		Total add'I fee	\$
	Please charge duplicate copy		count No. 23-192 t is enclosed.	25 (BRINKS HO	FER GILSON &	LIONE) in the	he am	ount of \$	A
	A check in the amount of \$ to cover the filling fee is enclosed.								
The Commissioner is hereby authorized to charge payment of any additional filing fees required unde 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communicat any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.								nmunication o	
Gregory M. Zinkl, Ph.D. Registration No. 48,492									
BRINKS H	IOFER GILSON & 10395	LIONE		Agent for Ap	plicant			-	
	, ILLINOIS 6061	0		. /					
express mail,		662US, with suf	deposited with the Unite						
Date: # \	126/12	Sionatu	Mrs.						



## United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023I
WWW.USDIO.GOV

APPLICATION NUMBER

FILING/RECEIPT DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

09/904.877

07/12/2001

Avi Ashknazi


P1618P2C27

**CONFIRMATION NO. 4450** 

FORMALITIES LETTER

OC000000007149313\*

Paul E. Rauch, Ph.D. Brinks, Hofer, Gilson & Lione NBC Tower - Suite 3600 455 Cityfront Plaza Drive Chicago, IL 60611-5599



Date Mailed: 12/03/2001

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

• A request to transfer the computer readable form from another application on file at the U.S. Patent and Trademark Office has been submitted as permitted by 37 C.F.R. 1.821(e). However, the request cannot be complied with since there is no compliant CRF present at the United States Patent and Trademark Office. Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice <u>MUST</u> be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY